

Ou Yamaguchi

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1050392/ou-yamaguchi-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

31
papers

583
citations

10
h-index

23
g-index

39
ext. papers

921
ext. citations

4.6
avg, IF

3.66
L-index

#	Paper	IF	Citations
31	Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. <i>Lancet Oncology</i> , 2019 , 20, 625-635	21.7	264
30	CD4 T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy. <i>Cancer Immunology Research</i> , 2020 , 8, 334-344	12.5	68
29	Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non-small cell lung cancer patients. <i>Thoracic Cancer</i> , 2019 , 10, 775-781	3.2	38
28	Radiotherapy is an independent prognostic marker of favorable prognosis in non-small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab. <i>Thoracic Cancer</i> , 2019 , 10, 992-1000	3.2	30
27	Phase II study of nab-paclitaxel+carboplatin for patients with non-small-cell lung cancer and interstitial lung disease. <i>Cancer Science</i> , 2019 , 110, 3738-3745	6.9	26
26	Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	20
25	Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2020 , 85, 761-771	3.5	19
24	Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019 , 84, 873-880	3.5	18
23	Different incidence of interstitial lung disease according to different kinds of EGFR-tyrosine kinase inhibitors administered immediately before and/or after anti-PD-1 antibodies in lung cancer. <i>Thoracic Cancer</i> , 2019 , 10, 975-979	3.2	16
22	Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non-small cell lung cancer: Management of adverse events. <i>Thoracic Cancer</i> , 2020 , 11, 1280-1287	3.2	13
21	Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥75 years) with non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020 , 146, 457-466	4.9	10
20	Tumor metabolic volume by F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ^{≥50} . <i>Scientific Reports</i> , 2020 , 10, 14990	4.9	6
19	Pre-existing interstitial lung disease does not affect prognosis in non-small cell lung cancer patients with PD-L1 expression ≥0% on first-line pembrolizumab. <i>Thoracic Cancer</i> , 2021 , 12, 304-313	3.2	6
18	Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With Mutations. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100107	1.4	6
17	Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non-small cell lung cancer harboring EGFR mutation. <i>Thoracic Cancer</i> , 2020 , 11, 1045-1051	3.2	5
16	Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naïve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort study. <i>European Journal of Cancer</i> , 2021 , 150, 63-72	7.5	5
15	Clinical significance of primary prophylactic pegylated-granulocyte-colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019 , 10, 1005-1008	3.2	4

14	Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation. <i>Cancer Chemotherapy and Pharmacology</i> , 2019 , 83, 817-825	3.5	4
13	Effectiveness of EGFR-TKI rechallenge immediately after PD-1 blockade failure. <i>Thoracic Cancer</i> , 2021 , 12, 864-873	3.2	4
12	A phase II study of first-line afatinib for patients aged ≥ 5 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027. <i>BMC Cancer</i> , 2021 , 21, 208	4.8	3
11	Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer. <i>Cancer Medicine</i> , 2021 , 10, 6971-6984	4.8	3
10	Efficacy and safety of S-1 monotherapy in previously treated elderly patients (aged ≥ 5 years) with non-small cell lung cancer: A retrospective analysis. <i>Thoracic Cancer</i> , 2020 , 11, 2867-2876	3.2	2
9	Post-Progression Survival Influences Overall Survival among Patients with Advanced Non-Small Cell Lung Cancer Undergoing First-Line Pembrolizumab Monotherapy. <i>Oncology</i> , 2021 , 99, 562-570	3.6	2
8	Tumor immunity is related to F-FDG uptake in thymic epithelial tumor. <i>Cancer Medicine</i> , 2021 , 10, 6317-6326	4.8	2
7	Pseudoprogression mimicking hyperprogressive disease after pembrolizumab treatment in a patient with lung cancer. <i>Lung Cancer</i> , 2020 , 139, 221-223	5.9	1
6	Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers. <i>Frontiers in Oncology</i> , 2021 , 11, 610952	5.3	1
5	Incidence and risk factors for pneumonitis among patients with lung cancer who received immune checkpoint inhibitors after palliative thoracic radiotherapy. <i>Journal of Radiation Research</i> , 2021 , 62, 669-675	2.4	1
4	Unexpected response of extramedullary plasmacytoma in patients with lung cancer who received nivolumab. <i>Annals of Hematology</i> , 2019 , 98, 2851-2852	3	1
3	Detection of pseudoprogression with [F]-FDG-PET in a patient with pulmonary large cell neuroendocrine carcinoma who received anti-PD-1 treatment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 1268-1270	8.8	1
2	Clinical impact of post-progression survival on overall survival in patients receiving nivolumab monotherapy as a second-line treatment for advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021 , 12, 1171-1179	3.2	1
1	Efficacy and Safety of Anti-Programed Death-1 Blockade in Previously Treated Large-Cell Neuroendocrine Carcinoma. <i>Chemotherapy</i> , 2021 , 66, 65-71	3.2	1